Evommune EBIT

Evommune (EVMN) currently reports a EBIT of $-80M as of March 2026. That compares with $-64M in the prior-year period — down 25.2% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Evommune's EBIT history and peer comparisons.

Evommune's EBIT decreased from $-64M to $-80M — a 25.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evommune's EBIT of $-80M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Evommune reported $-80M in EBIT as of March 2026. That compares with $-64M in the prior-year period — down 25.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-80M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Evommune, and consider following EVMN for alerts when major investors trade the stock.